Your Genes Matter
If we want to understand prostate cancer, we have to understand genes. That’s why the genes of prostate cancer patients are so important. They represent the next step in our collective fight against this disease.
PROMISE is creating a coalition across institutions, and we’re building a genetic database directly from a grassroots network of patients so that every prostate cancer patient who is interested can better understand their genetic risk and potential treatment options. When we can analyze genetic information from partners around the country, we will be setting the foundation for the future of prostate cancer knowledge and treatment.
Your Genes Matter
If we want to understand prostate cancer, we have to understand genes. That’s why the genes of prostate cancer patients are so important. They represent the next step in our collective fight against this disease.
PROMISE is creating a coalition across institutions, and we’re building a genetic database directly from a grassroots network of patients so that every prostate cancer patient who is interested can better understand their genetic risk and potential treatment options. When we can analyze genetic information from partners around the country, we will be setting the foundation for the future of prostate cancer knowledge and treatment.
Our World-Class Researchers
Oncology experts from around the country have come together to improve our understanding of the critical role of genes in prostate cancer.
PROMISE researchers will share the key findings from the study with other prostate cancer researchers to help accelerate advancements in knowledge and treatment.
Channing Judith Paller, M.D.
Dr. Channing J. Paller is an associate professor of oncology and urology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and an expert on biomarkers that enable patient-centered treatment strategies. Her research focuses on developing improved, targeted treatments to extend survival and improve quality of life for prostate cancer patients.
Read More +Informed by her expertise in prostate, bladder, kidney and testicular cancer, Dr. Paller’s research focuses on evaluating new therapies for prostate cancer, particularly combination therapies that engage the immune system.
After earning her medical degree from Harvard Medical School and completing a residency in internal medicine, Dr. Paller began a fellowship in hematology and oncology at Johns Hopkins University School of Medicine. She is board certified in both internal medicine and medical oncology.
In 2016, Dr. Paller was one of only five oncologists awarded the NCI Mentored Patient-Oriented Research Career Development Award. She received the 2015 Passano Clinician Scientist Award for early stage research that is already making a contribution to science.
Heather Cheng, M.D., Ph.D.
Dr. Heather Cheng focuses on improving the care of patients with prostate and bladder cancers. An expert in prostate cancer genetics, she is studying ways to use genetics to guide the care of prostate cancer patients and their family members who may also be at high risk for the disease.
Read More +Dr. Cheng leads clinical trials of a variety of new treatments for prostate cancer. She is also developing new tests that could help guide doctors’ choice of treatment for each patient and new blood tests to detect and monitor the progression of prostate cancer.
Her expertise ranges from treatment of prostate cancer, to bladder cancer, testicular cancer, early-onset, aggressive prostate cancer, and familial and hereditary prostate cancer.
After earning her MD and PhD in Molecular and Cellular Biology at the University of Washington in Seattle, Washington, Dr. Cheng did her internship and Residency in Internal Medicine at the University of Washington, as well as a Fellowship in Hematology-Oncology.